Ginkgo Bioworks shares are trading higher after the company announced it launched a protein LLM and model API build on Google Cloud to accelerate drug development.
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks shares rose following the launch of a protein LLM and model API on Google Cloud, aimed at speeding up drug development.
September 17, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ginkgo Bioworks' stock is up due to the launch of a protein LLM and model API on Google Cloud, which is expected to enhance drug development processes.
The launch of a new product on a major platform like Google Cloud is a significant development for Ginkgo Bioworks, likely to enhance its capabilities in drug development and attract investor interest, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100